Linear regression for systolic blood pressure, test for additive allele effects, subcohort without individuals on treatment for high blood pressure

Rank SNP name in MORGAM RS-code Chromosome Success Genotype N Mean coef (95% CI) nominal p-value tail-area FDR
1 2Q36_3_MG_433 rs2972147 2 98.5% C/C 747 138.919 -1.633
(-2.884, -0.382)		 0.01051 0.15762
C/T 861 140.811
T/T 249 141.661
2 SMAD3_MG_424 rs12913547 15 99.6% C/C 128 142.078 1.760
(0.389, 3.131)		 0.01186 0.15762
C/T 740 141.657
T/T 1010 138.747
3 2Q36_3_MG_461 rs2943634 2 97.8% A/A 225 141.860 1.603
(0.332, 2.874)		 0.01343 0.15762
A/C 850 140.708
C/C 769 139.036
4 MTHFD1L_MG_423 rs12525353 6 99.4% A/A 2 159.000 -5.198
(-9.387, -1.009)		 0.01501 0.15762
A/C 72 133.958
C/C 1801 140.365
5 5Q21_1_MG_436 rs449650 5 99.0% G/G 1173 139.301 -1.284
(-2.729, 0.161)		 0.08147 0.60604
G/T 597 141.472
T/T 97 141.887
6 5Q21_1_MG_455 rs383830 5 99.0% A/A 96 142.083 1.261
(-0.181, 2.703)		 0.08658 0.60604
A/T 599 141.346
T/T 1173 139.317
7 5Q21_1_MG_435 rs436495 5 98.8% A/A 109 141.908 1.154
(-0.260, 2.568)		 0.10979 0.65874
A/G 655 141.505
G/G 1099 139.254
8 5Q21_1_MG_441 rs565928 5 99.5% C/C 1175 139.389 -1.077
(-2.523, 0.368)		 0.14394 0.75567
C/T 606 141.365
T/T 96 141.281
9 10Q11_21_MG_439 rs501120 10 96.4% C/C 47 138.809 1.142
(-0.556, 2.840)		 0.18736 0.75841
C/T 445 141.820
T/T 1327 139.672
10 SMAD3_MG_452 rs17228212 15 99.2% C/C 100 135.835 -0.903
(-2.347, 0.540)		 0.22010 0.75841
C/T 665 139.526
T/T 1105 140.849
11 2Q36_3_MG_447 rs7597168 2 99.4% C/C 1047 139.492 -0.882
(-2.292, 0.529)		 0.22057 0.75841
C/T 720 140.964
T/T 107 140.584
12 12Q12_MG_448 rs7970834 12 99.5% G/G 581 140.428 0.699
(-0.532, 1.931)		 0.26556 0.75841
G/T 949 140.716
T/T 347 138.053
13 1Q31_2_MG_453 rs1936982 1 99.0% C/C 237 140.057 -0.692
(-1.934, 0.550)		 0.27481 0.75841
C/T 820 139.376
T/T 811 140.807
14 10Q11_21_MG_440 rs559580 10 99.0% C/C 48 138.854 0.862
(-0.779, 2.504)		 0.30321 0.75841
C/T 501 141.401
T/T 1318 139.656
15 10Q11_21_MG_443 rs687175 10 99.5% C/C 48 138.854 0.848
(-0.787, 2.484)		 0.30940 0.75841
C/T 507 141.343
T/T 1322 139.705
16 10Q11_21_MG_428 rs1746048 10 99.5% C/C 1324 139.685 -0.797
(-2.438, 0.845)		 0.34143 0.75841
C/T 505 141.430
T/T 47 138.234
17 10Q11_21_MG_432 rs2146807 10 99.3% C/C 14 131.643 -1.029
(-3.151, 1.092)		 0.34167 0.75841
C/T 311 138.720
T/T 1547 140.516
18 10Q11_21_MG_458 rs622472 10 98.5% A/A 1303 139.732 -0.785
(-2.414, 0.844)		 0.34497 0.75841
A/C 504 141.268
C/C 50 138.980
19 9P21_3_MG_420 rs10738610 9 99.1% A/A 628 140.627 -0.585
(-1.815, 0.645)		 0.35124 0.75841
A/C 915 139.817
C/C 326 140.321
20 SEZ6L_MG_457 rs6005016 22 98.9% A/A 4 141.000 -1.438
(-4.617, 1.741)		 0.37543 0.75841
A/G 128 138.336
G/G 1734 140.266
21 10Q11_21_MG_429 rs1746049 10 99.5% C/C 1428 139.893 -0.806
(-2.603, 0.991)		 0.37921 0.75841
C/T 418 141.237
T/T 31 136.323
22 10Q11_21_MG_456 rs513391 10 99.1% A/A 1316 139.776 -0.700
(-2.330, 0.929)		 0.39956 0.76279
A/C 504 141.222
C/C 49 138.469
23 MIA3_MG_454 rs3008621 1 98.5% A/A 47 142.319 0.612
(-1.081, 2.304)		 0.47870 0.83850
A/G 443 141.133
G/G 1368 139.771
24 MIA3_MG_430 rs17465637 1 99.3% A/A 134 138.828 -0.490
(-1.847, 0.867)		 0.47914 0.83850
A/C 683 140.038
C/C 1055 140.365
25 9P21_3_MG_425 rs1333049 9 99.6% C/C 316 140.603 0.410
(-0.818, 1.638)		 0.51286 0.84474
C/G 915 139.484
G/G 647 140.785
26 9P21_3_MG_421 rs10757283 9 99.4% C/C 548 140.855 0.372
(-0.856, 1.601)		 0.55230 0.84474
C/T 950 139.643
T/T 376 140.229
27 PSRC1_MG_460 rs599839 1 99.5% A/A 1080 140.168 0.410
(-0.976, 1.796)		 0.56220 0.84474
A/G 679 140.308
G/G 117 137.940
28 9P21_3_MG_459 rs7865618 9 98.8% A/A 613 139.856 -0.340
(-1.541, 0.861)		 0.57889 0.84474
A/G 900 140.231
G/G 351 140.174
29 FMN2_MG_450 rs1456648 1 98.7% G/G 45 142.022 -0.467
(-2.133, 1.200)		 0.58327 0.84474
G/T 484 139.700
T/T 1332 140.160
30 SEZ6L_MG_442 rs6005015 22 99.5% C/C 167 139.796 -0.272
(-1.598, 1.054)		 0.68772 0.96046
C/T 823 139.605
T/T 887 140.671
31 SMAD3_MG_431 rs1866317 15 99.5% C/C 30 143.267 -0.285
(-2.060, 1.490)		 0.75288 0.96046
C/G 453 140.083
G/G 1394 140.081
32 SEZ6L_MG_444 rs688034 22 99.5% C/C 976 140.673 -0.208
(-1.587, 1.171)		 0.76731 0.96046
C/T 769 139.557
T/T 131 139.519
33 MTHFD1L_MG_445 rs6922269 6 99.3% A/A 99 139.631 0.184
(-1.251, 1.618)		 0.80200 0.96046
A/G 665 139.601
G/G 1109 140.478
34 SEZ6L_MG_426 rs137205 22 99.5% A/A 144 140.139 0.150
(-1.204, 1.505)		 0.82785 0.96046
A/G 806 139.767
G/G 926 140.494
35 MTHFD1L_MG_449 rs12214306 6 99.2% C/C 0   0.290
(-3.692, 4.272)		 0.88659 0.96046
C/T 89 140.090
T/T 1782 140.109
36 CELSR2_MG_434 rs413380 1 99.5% C/C 1702 140.064 -0.192
(-2.887, 2.504)		 0.88908 0.96046
C/T 165 140.721
T/T 10 141.600
37 9P21_3_MG_437 rs496892 9 99.0% C/C 479 139.736 -0.081
(-1.293, 1.132)		 0.89611 0.96046
C/T 951 140.486
T/T 437 139.874
38 19Q12_MG_422 rs11670734 19 99.5% C/C 142 138.169 -0.088
(-1.443, 1.267)		 0.89878 0.96046
C/G 759 139.995
G/G 976 140.525
39 SEZ6L_MG_427 rs137209 22 99.6% A/A 185 139.324 -0.078
(-1.389, 1.234)		 0.90766 0.96046
A/G 865 139.905
G/G 828 140.524
40 CELSR2_MG_438 rs4970834 1 99.4% C/C 1174 140.024 0.082
(-1.417, 1.581)		 0.91472 0.96046
C/T 626 140.524
T/T 75 138.200
41 9P21_3_MG_451 rs1537378 9 98.1% A/A 282 139.589 0.016
(-1.225, 1.256)		 0.98011 0.99716
A/G 892 140.362
G/G 676 140.111
42 19Q12_MG_446 rs7250581 19 97.9% A/A 46 140.522 -0.003
(-1.717, 1.710)		 0.99716 0.99716
A/G 430 140.023
G/G 1371 140.267

adjusted for: cohort age1 sex

Updated on 2008-12-08